Compare DuPont de Nemours Inc (DD) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Oscar Health Inc — how do they compare? DuPont de Nemours Inc trades at $144.26 (market cap $19.12B), while Oscar Health Inc trades at $27.93 (market cap $8.54B). The key difference: DuPont de Nemours Inc is far larger — about 2.2× Oscar Health Inc's market cap, and DuPont de Nemours Inc pays a 1.7% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| DD | OSCR | |
|---|---|---|
Market Cap | $19.12B | $8.54B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $32.18 |
52-Week Low | $90.24 | $10.85 |
Enterprise Value | $20.50B | $4.90B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.
The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.
OSCR trades at $27.90, up 5.12% with strong recent earnings performance including Q2 2026 EPS beating estimates. The stock shows bearish technical signals but positive fundamental momentum with revenue growth from $11.7B to $15.3B and a swing to profitability. Recent news highlights record 2026 profitability and raised full-year guidance.
The outlook appears constructive with analyst consensus target of $32.50 offering 16% upside. Key risks include execution on growth targets and competitive pressures. The valuation remains attractive with P/S of 0.53, though investors should monitor Q3 earnings delivery against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
